Overview

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Status:
Recruiting
Trial end date:
2026-08-03
Target enrollment:
Participant gender:
Summary
This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study (eg. DS8201-A-J101, DS8201-A-U201, DS8201-A-U204, DS8201-A-U207, DS8201-A-U303).
Phase:
Phase 3
Details
Lead Sponsor:
Daiichi Sankyo
Collaborator:
AstraZeneca
Treatments:
Trastuzumab deruxtecan